share_log

Advaxis (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Advaxis (NASDAQ:ADXS) Coverage Initiated at StockNews.com

AdvAxis(納斯達克股票代碼：ADXS)在StockNews.com上開始報道
kopsource ·  2022/09/20 01:31

StockNews.com assumed coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a report published on Friday. The firm issued a sell rating on the stock.

斯托克新聞網在週五發佈的一份報告中對Advaxis(納斯達克：ADXS-GET Rating)的股票進行了報道。該公司對該股發佈了賣出評級。

Advaxis Price Performance

Advaxis性價比

Shares of ADXS stock opened at $2.86 on Friday. The company has a market cap of $5.19 million, a P/E ratio of -0.32 and a beta of 2.20. Advaxis has a twelve month low of $1.02 and a twelve month high of $44.80.

上週五，ADXS股票開盤報2.86美元。該公司市值為519萬美元，市盈率為-0.32，貝塔係數為2.20。Advaxis的12個月低點為1.02美元，12個月高位為44.80美元。

Get
到達
Advaxis
前進軸
alerts:
警報：

Advaxis Company Profile

Advaxis公司簡介

(Get Rating)

(獲取評級)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis，Inc.是一家臨牀階段的生物技術公司，專注於在美國發現、開發和商業化專有的單核細胞增生性李斯特菌(LM)技術抗原遞送產品。該公司正在開發ADXS-PSA，這是用於治療轉移性前列腺癌的第二階段臨牀試驗；ADXS-503，用於治療非小細胞肺癌；以及ADXS-504，用於治療前列腺癌。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Advaxis (ADXS)
  • Lucid is Looking Like a Clear EV Winner
  • Still Lovin' It: Investors Keep Visiting McDonald's
  • Did FedEx Just Deliver A Buying Opportunity?
  • Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
  • Upwork Shares Stumble into Bargain Territory
  • 免費獲取StockNews.com關於Advaxis的研究報告(ADXS)
  • Lucid看起來像是電動汽車的贏家
  • 仍然愛着它：投資者繼續光顧麥當勞
  • 聯邦快遞剛剛提供了一個買入機會嗎？
  • 自動區重新進入拉力賽模式，新高在望
  • Upwork股價跌入便宜貨領域

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

接受Advaxis Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Advaxis和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論